Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atumelnant study in adults with classic congenital adrenal hyperplasia
2024-519579-24-00Phase 3Authorised
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in classic congenital adrenal hyperplasia comparing Atumelnant with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Feb 2026; status: authorised.
02
Drugs
atumelnant
03
Conditions
classic congenital adrenal hyperplasia
Beyond the preview
Go deeper on 2024-519579-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519579-24-00.